OSEIN does not provide investment advice, and the information contained in this memo should not be solely relied upon for making investment decisions. Investors are encouraged to conduct their own due diligence and seek professional advice before making any investment. OSEIN does not assume any liability or responsibility for investment outcomes. Additionally, AI was used to review, synthesize, and prepare the following information.
Investing in early-stage and angel investments is inherently risky, and investors should be aware that they may lose their entire investment. By proceeding with any investment, investors acknowledge and assume these risks and understand that the outcomes can be unpredictable and may not result in financial gain.
Link: Pitch Recording (password: OSEIN)
April 10, 2026 Updates:
Product & Engineering Progress
We’ve completed our Asterra benchmark testing, and Gravitone 2.0 is now ready for wear testing. This version is currently being used as our internal testbed to inform both product performance and future medical development.
In parallel, Asterra 2.0 is entering small-scale manufacturing ahead of upcoming pilots. We are actively collecting vendor quotes and building out initial production capabilities in San Francisco. Early unit economics are shaping up as follows:
These early numbers give us confidence in both the near-term pilot model and long-term scalability.
Application Development
We’ve also developed a companion application in collaboration with Ohio State capstone students. The app predicts seasickness susceptibility using vessel data, geopositioning, and user demographics, and can prompt users to proactively use the device.
Longer term, we see this as both a product enhancement and a lightweight entry point for customer engagement—allowing us to build brand awareness even before direct device use.
Pilots & Industry Engagement
We’re currently finalizing pilot timelines for this summer, including:
The crew use case continues to stand out as particularly compelling. Many seafarers are restricted from using traditional motion sickness medications while on duty, creating a strong need for a non-pharmaceutical, real-time solution. We’re increasingly exploring how to position Asterra as both a safety and productivity tool in these environments.
On the commercial side, our perspective has evolved. While we initially focused on expedition and luxury segments, recent traction—especially following our engagement with the Cruise Line International Association (CLIA)—has opened conversations with larger operators including MSC Virgin Voyages, and Norwegian Cruise Line, as well as broader distribution groups.
We’re using this phase to intentionally test multiple segments (crew, medical, retail, expedition, and large cruise lines) before committing to a primary go-to-market path. I’ll be continuing these conversations this week at Seatrade in Miami.
Research Partnerships
We’re also launching a new research collaboration with the Reykjavik University Institute of Biomedical and Neural Engineering, alongside our ongoing work with Ohio State.
This work centers around BioVRSea, a virtual reality and motion-platform system that simulates maritime conditions in a controlled environment. It allows us to measure balance and postural responses using biosignals such as EMG, EEG, and heart rate.
This approach enables us to:
We’ll be in Reykjavik in May to begin early development work, followed by a 15–25 participant study shortly after.
Website: https://www.avionova.tech/
LinkedIn: https://www.linkedin.com/company/avionova/
Business Overview:
Avionova is a Columbus, Ohio–based medical technology startup developing noninvasive wearable earbuds designed to stabilize the inner ear and reduce vertigo, balance loss, and motion sickness. The company’s proprietary technology uses precise, localized cooling to address vestibular hyperactivity without medication or sedation. Avionova operates a dual-track strategy across medical and wellness markets, targeting patients with vestibular disorders such as Ménière’s disease, vestibular neuritis, and vestibular migraine, as well as travelers experiencing motion sickness and spatial disorientation in high-motion environments.
Overall Raise:
Avionova is raising $500,000 via a SAFE to fund approximately 14–16 months of operations. Proceeds will support core team costs, matched R&D services through the JumpStart Titanium program, execution of feasibility studies, and pilot manufacturing of its wellness device. To date, the company has raised approximately $120,000 in prior funding.
Form of Business Entity:
C Corporation.
Patent Status:
Proprietary technology with one provisional patent filed and additional patent applications in progress covering localized cryotherapy methods for vestibular stabilization and related device configurations.
Customer Base:
Avionova serves two primary customer segments. In the medical market, customers include clinicians and patients treating vestibular disorders, a category affecting nearly 40 percent of Americans and associated with an estimated $60 billion annual economic burden in the U.S. In the wellness and travel market, customers include expedition cruise operators and travelers seeking non-pharmaceutical motion sickness prevention. The company currently has pilots underway with cruise operators and is in active discussions with additional partners.